Real World Evidence Solutions Market Size, Share, By Component (Claims Data, Clinical Settings Data, Patient-Powered Data, Pharmacy Data, and Others), By Application (Drug Development, and Drug Approvals), By End- Use (Healthcare Payers, Healthcare Providers, Pharmaceutical and Medical Device Companies, and Others), and By Region (North America, Europe, Asia Pacific, Middle East and Africa, and South America) - Trends, Analysis and Forecast till 2034

Real World Evidence Solutions Market Size was valued at USD 3 Billion in 2024 and is expected to reach USD 9.7 Billion by 2034, growing at a CAGR of 13.8%.

Real-world evidence (RWE) is clinical evidence from examining real-world data (RWD) on patient health and healthcare delivery. It provides information about how a medical product should be used and any possible hazards or advantages. Outside of the controlled setting of clinical trials, real-world evidence aids healthcare organizations in comprehending and establishing more significant evidence of a product's performance, clinical value, and cost-effectiveness. Real-world data and evidence are becoming increasingly important to outcome-based research to expedite drug approvals and development, lowering development costs.

RWE systems have been extensively employed to facilitate safety surveillance studies after approval. To assess pharmaceuticals' efficacy, international authorities have recently begun incorporating RWE systems into drug development and various stages of the drug life cycle. RWE solutions are used in several nations for post-marketing efficaciousness evaluation and pharmacovigilance initiatives.

It is projected that increased R&D spending and regulatory bodies' support for real-world evidence (RWE) solutions will propel market expansion. Furthermore, market expansion is anticipated as value-based care replaces volume-based treatment. Challenges include poor infrastructure in some areas and worries about data privacy. Because of increased government support and healthcare spending, emerging countries in the Middle East, Africa, and Asia Pacific region have enormous development potential. Data management and analytics developments can further unlock the potential of RWE solutions for enhancing healthcare outcomes.

Key Drivers of Target Market:

Usage in Drug Research & Approvals:

• Randomized controlled clinical trials (RCTs) are a significant component of traditional drug research, as they help determine the safety and effectiveness of new drugs. RWE data, on the other hand, offers information on how drugs function in actual clinical practice, including a range of patient demographics and situations. RCTs have limitations. This makes evaluating a drug's efficacy easier outside of an RCT's controlled setting.

Growth of Value-Based Care:

• Providers are frequently compensated under the traditional healthcare paradigm according to the amount of services they do (fee-for-service). This may encourage pointless tests and procedures, raising healthcare expenditures without necessarily improving patient outcomes. Value-based treatment aims to provide high-quality medical care at a lower cost while improving patient outcomes. Identifying cost-effective interventions is a critical function of RWE solutions in this change. It is possible to evaluate the cost-effectiveness of different therapies using RWE data. Payers and healthcare providers can use this information to select most cost-effective interventions.

Restrains:

Worries regarding data privacy:

• Data privacy concerns are one major obstacle facing the Real World Evidence (RWE) solutions market. Patients must give their informed consent before using their anonymized data for RWE analysis, but the procedure can be difficult and time-consuming, mainly when dealing with big datasets. Furthermore, the possibility of re-identification exists even using anonymization approaches, especially when dealing with detailed datasets. This raises concerns over possible patient data misuse.

Opportunities:

Increasing initiatives in public health:

• A broad range of actions is included in public health programs with the goal of preserving and enhancing population health. With data-driven insights, the Real World Evidence (RWE) solutions market offers a unique chance to improve these programs' efficacy. Real-time identification of developing disease epidemics is possible with RWE systems because they can analyze data from several sources, including wearable sensors, pharmacy data, and patient records. This makes it possible for public health professionals to quickly stop the spread of illnesses.

The market is segmented based on Component, Application, End-use, and Region.

Component Insight:

• Claims Data: The most often utilised component, claims data, includes details on medical claims filed with insurance companies. It provides information on treatment costs, patient outcomes in actual situations, and patterns of healthcare utilization.
• Clinical Settings Data: Clinical Settings include electronic health records (EHRs) and other data gathered from clinics, hospitals, and other healthcare facilities comprise the data. This information gives patients comprehensive details about their diagnosis, treatments, prescriptions, and test results. These data make a thorough study of therapy efficacy and safety in clinical settings possible.
• Patient-Powered Data: The Patient-Powered Data segment uses wearable technology, smartphone apps, or surveys to collect patient data directly. It offers insightful information about patient experiences, treatment compliance, and quality of life.
• Pharmacy Data: Pharmacy data, which is information gathered from pharmacies about drugs they have dispensed, is helpful in tracking medicine usage trends, spotting possible drug interactions, and keeping an eye on patients' compliance with prescription regimens.
• Others: Additional categories of data that provide more information about patient health and behaviour include registries, social media sources (where anonymized and properly acquired), and wearable sensor data.

Application Insights

• Drug Development: Traditionally, controlled clinical trials have been the mainstay of drug research and development, but their scope and cost might be restricted. This is where Real-World Evidence (RWE) comes in, providing information on how drugs work with a range of patients in real-world settings.
• Drug Approvals: Regulators are embracing RWE's importance.  By adding to clinical trials, this data may speed up the approval process for drugs with good safety and efficacy profiles in the real world.  Moreover, RWE permits continuous evaluation of a medication's efficacy and safety following its release.

End-Use Insights

• Healthcare Payers: Due to payers' growing knowledge of the significance of medical device/drug safety, their negative consequences, and good reimbursement scenarios, particularly in developed nations, the healthcare payers segment is predicted to grow at the quickest CAGR throughout the projection period.
• Healthcare Providers: By utilising RWE technologies, healthcare providers, such as physicians, clinics, and hospitals, can compare treatment outcomes for various patient populations, learn from best practices, and enhance the quality of care they provide.
• Pharmaceutical and Medical Device Companies: RWE solutions are used by pharmaceutical and medical device companies to track how well their goods are performing on the market, pinpoint areas for development, and create focused marketing campaigns.
• Others: RWE products are also used by other end-user sectors, such as government organizations, patient advocacy organizations, and research institutes, for various tasks, including performing health research, influencing public health policies, and enhancing patient outcomes.

Regional Insights

• North America: With a substantial revenue share, North America led the market for real-world evidence solutions. It held the most market share worldwide, attributable to regulatory agencies' strong backing of RWE solution use. In addition, the transition from volume-based to value-based care and higher R&D expenditures support the market's expansion.
• Asia Pacific: Regarding real-world evidence solutions, Asia Pacific is expected to expand fastest during the projected timeframe. Growth can be attributed to the numerous contract research and manufacturing organizations in nations like China and India and the growing government push to implement RWE studies.
• Europe: Over the projected period, the real-world evidence solutions market in Europe is anticipated to grow significantly. The rapid increase in the region's senior population and the rising prevalence of infectious and chronic diseases can be blamed for the market's growth. Hospital visits have also increased.
• Latin America: While data privacy issues and a lack of adequate technology infrastructure pose hurdles for Latin America's expanding industry, throughout the projected period, there will also be a growing understanding of the advantages of RWE.
• Middle East and Africa: Although there is currently little RWE usage in the Middle East and Africa region, there is potential for growth in the future as healthcare infrastructure improves.

Real World Evidence Solutions Market Report Scope:

Attribute	Details
Market Size 2024	USD 3 Billion
Projected Market Size 2034	USD 9.7 Billion
CAGR Growth Rate	13.8%
Base year for estimation	2023
Forecast period	2024 – 2034
Market representation	Revenue in USD Billion & CAGR from 2024 to 2034
Market Segmentation	By Component - Claims Data, Clinical Settings Data, Patient-Powered Data, Pharmacy Data, and Others By Application – Drug Development and Drug Approvals By End- Use - Healthcare Payers, Healthcare Providers, Pharmaceutical and Medical Device Companies, and Others
Regional scope	North America - U.S., Canada Europe - UK, Germany, Spain, France, Italy, Russia, Rest of Europe Asia Pacific - Japan, India, China, South Korea, Australia, Rest of Asia-Pacific Latin America - Brazil, Mexico, Argentina, Rest of Latin America Middle East & Africa - South Africa, Saudi Arabia, UAE, Rest of Middle East & Africa
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends

Segments Covered in the Report:

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2024 to 2034. For the purpose of this study segmented the target market report based on Component, Application, End- Use, and Region:

Segmentation:

By Component:

• Claims Data
• Clinical Settings Data
• Patient-Powered Data
• Pharmacy Data
• Others

By Application:

• Drug Development
• Drug Approvals

By End-Use:

• Healthcare Payers
• Healthcare Providers
• Pharmaceutical and Medical Device Companies
• Others

By Region:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Russia
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • Israel
  • South Africa
  • Rest of Middle East & Africa

The key players operating the Real World Evidence Solutions Market include IQVIA Inc., IBM, PPD, Inc., Parexel International (MA) Corporation, PerkinElmer Inc., ICON plc, Oracle, Syneos Health, Cegedim Health Data, Medpace, and Clinigen Group.

• In April 2024, Palantir Technologies Inc. and Parexel joined to use AI to speed up and improve the delivery of efficient and secure clinical trials for clients in the global biopharmaceutical industry. Through the partnership, Paraxel's strengths in advanced analytics, RWE, and health outcomes are expanded, and improved clinical trial processes are made possible.
• In April 2024, IQVIA and Salesforce announced they would expand their strategic cooperation to accelerate the development of Salesforce's Life Sciences Cloud. This project is a next-generation platform for consumer engagement in the life sciences industry. Using these tactical alliances, IQVIA hopes to create further technology-based solutions that will quicken decision-making procedures in several areas, including RWE, discovery, clinical development, medical affairs, and patient safety.
• In October 2021, The Real-World Evidence Registry was introduced by the Real-World Evidence Transparency Initiative to create a transparent culture for reporting and analyzing real-world evidence in medical research and healthcare. The International Society for Pharmacoepidemiology, the National Pharmaceutical Council, the Duke-Margolis Centre for Health Policy, and ISPOR collaborate to create the Real-World Evidence Transparency Initiative.

• IQVIA Inc.*
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• IBM
• PPD, Inc.
• Parexel International (MA) Corporation
• PerkinElmer Inc.
• ICON plc
• Oracle
• Syneos Health
• Cegedim Health Data
• Medpace
• Clinigen Group

“*” marked represents similar segmentation in other categories in the respective section

1. Research Objective and Assumption
   • Research Objectives
   • Assumptions
   • Abbreviations
2. Market Preview
   • Report Description
     • Market Definition and Scope
   • Executive Summary
     • Market Snippet, By Component
     • Market Snippet, By Application
     • Market Snippet, By End-Use
     • Market Snippet, By Region
   • Opportunity Map Analysis
3. Market Dynamics, Regulations, and Trends Analysis
   • Market Dynamics
     • Drivers
     • Restraints
     • Market Opportunities
   • Market Trends
   • Product Launch
   • Merger and Acquisitions
   • Impact Analysis
   • PEST Analysis
   • Porter’s Analysis
4. Market Segmentation, Component, Forecast Period up to 10 Years, (US$ Bn)
   • Overview
     • Market Value and Forecast (US$ Bn), and Share Analysis (%), Forecast Period up to 10 Years
     • Y-o-Y Growth Analysis (%), Forecast Period up to 10 Years
     • Segment Trends
   • Claims Data
     • Overview
     • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
   • Clinical Settings Data
     • Overview
     • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
     • Segment Trends
   • Patient-Powered Data
     • Overview
     • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
     • Segment Trends
   • Pharmacy Data
     • Overview
     • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
     • Segment Trends
   • Others
     • Overview
     • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
     • Segment Trends
5. Market Segmentation, Application, Forecast Period up to 10 Years, (US$ Bn)
   • Overview
     • Market Value and Forecast (US$ Bn), and Share Analysis (%), Forecast Period up to 10 Years
     • Y-o-Y Growth Analysis (%), Forecast Period up to 10 Years
     • Segment Trends
   • Drug Development
     • Overview
     • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
   • Drug Approvals
     • Overview
     • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
     • Segment Trends
6. Market Segmentation, End-Use, Forecast Period up to 10 Years, (US$ Bn)
   • Overview
     • Market Value and Forecast (US$ Bn), and Share Analysis (%), Forecast Period up to 10 Years
     • Y-o-Y Growth Analysis (%), Forecast Period up to 10 Years
     • Segment Trends
   • Healthcare Payers
     • Overview
     • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
   • Healthcare Providers
     • Overview
     • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
   • Pharmaceutical and Medical Device Companies
     • Overview
     • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
   • Others
     • Overview
     • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
7. Global Market, By Region, Forecast Period up to 10 Years, (US$ Bn)
   • Overview
     • Market Value and Forecast (US$ Bn), and Share Analysis (%), Forecast Period up to 10 Years
     • Y-o-Y Growth Analysis (%), Forecast Period up to 10 Years
     • Regional Trends
   • North America
     • Market Size and Forecast (US$ Bn), By Component, Forecast Period up to 10 Years
     • Market Size and Forecast (US$ Bn), By Application, Forecast Period up to 10 Years
     • Market Size and Forecast (US$ Bn), By End- Use, Forecast Period up to 10 Years
     • Market Size and Forecast (US$ Bn), By Country, Forecast Period up to 10 Years
       • U.S
       • Canada
   • Asia Pacific
     • Market Size and Forecast (US$ Bn), By Component, Forecast Period up to 10 Years
     • Market Size and Forecast (US$ Bn), By Application, Forecast Period up to 10 Years
     • Market Size and Forecast (US$ Bn), By End- Use, Forecast Period up to 10 Years
     • Market Size and Forecast (US$ Bn), By Country, Forecast Period up to 10 Years
       • India
       • Japan
       • South Korea
       • China
       • Rest of Asia Pacific
   • Europe
     • Market Size and Forecast (US$ Bn), By Component, Forecast Period up to 10 Years
     • Market Size and Forecast (US$ Bn), By Application, Forecast Period up to 10 Years
     • Market Size and Forecast (US$ Bn), By End- Use, Forecast Period up to 10 Years
     • Market Size and Forecast (US$ Bn), By Country, Forecast Period up to 10 Years
       • UK
       • Germany
       • France
       • Russia
       • Italy
       • Rest of Europe
   • Latin America
     • Market Size and Forecast (US$ Bn), By Component, Forecast Period up to 10 Years
     • Market Size and Forecast (US$ Bn), By Application, Forecast Period up to 10 Years
     • Market Size and Forecast (US$ Bn), By End- Use, Forecast Period up to 10 Years
     • Market Size and Forecast (US$ Bn), By Country, Forecast Period up to 10 Years
       • Brazil
       • Mexico
       • Rest of Latin America
   • Middle East and Africa
     • Market Size and Forecast (US$ Bn), By Component, Forecast Period up to 10 Years
     • Market Size and Forecast (US$ Bn), By Application, Forecast Period up to 10 Years
     • Market Size and Forecast (US$ Bn), By End- Use, Forecast Period up to 10 Years
     • Market Size and Forecast (US$ Bn), By Country, Forecast Period up to 10 Years
       • GCC
       • Israel
       • South Africa
       • Rest of Middle East and Africa
8. Competitive Landscape

• Heat Map Analysis
• Company Profiles
  • IQVIA Inc.
  • IBM
  • PPD, Inc.
  • Parexel International (MA) Corporation
  • PerkinElmer Inc.
  • ICON plc
  • Oracle
  • Syneos Health
  • Cegedim Health Data
  • Medpace
  • Clinigen Group

The Last Word

• Future Impact
• About Us
• Contact